PREPARATION AND EVALUATION OF IGURATIMOD ORAL FORMULATION USING CYCLODEXTRIN NANOSPONGES

Objective: Cyclodextrin nanosponges have unfolded themselves as budding delivery aids for intractable molecules that face difficulty in formulation. Methods: The present research aimed at the preparation of cyclodextrin-based employing diphenyl carbonate crosslinker reported elsewhere. Box-Behnken design was adopted to evaluate effects factors (reaction temperature, reaction time and stirring speed) on practical yield particle size. Based a numerical optimization technique, five batches nanosponge formulations with varying molar ratios (1:2, 1:4, 1:6, 1:8 1:10) were formulated evaluated. Results: drug loading into optimized β–CD (NS14, NS16) carried out by freeze-drying method maximum 32% displayed IGNS14. sizes Iguratimod-loaded range between 178 181 nm lower polydispersity indices. formulation IGNS14 IGNS16 optimal zetapotential of-27 and-26 mV, which is sufficient stabilize colloidal nanosuspension. dissolution both significantly higher (>98%) controlled when compared pure (34%). Retention observed, released slowly over time. PXRD confirm formation paracrystalline are spherical shape no interaction amongst excipients. Conclusion: NS Iguratimod probable alternative improved physicochemical properties therapeutic efficacy.